Baicalin inhibits breast cancer development via inhibiting IĸB kinase activation in vitro and in vivo

  • Authors:
    • Yang Gao
    • Hui Liu
    • Hongzhi Wang
    • Hailong Hu
    • Hongjuan He
    • Ning Gu
    • Xiao Han
    • Qian Guo
    • Dong Liu
    • Shuang Cui
    • Hongjiang Shao
    • Chengjun Jin
    • Qiong Wu
  • View Affiliations

  • Published online on: October 12, 2018     https://doi.org/10.3892/ijo.2018.4594
  • Pages: 2727-2736
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the effect and therapeutic potential of baicalin in breast cancer. Baicalin is used to treat inflammatory diseases. The effects of baicalin were assessed in breast cancer MCF-7 and MDA-MB‑231 cells, and human breast cancer xenograft mice. Cells were treated with 0, 20 or 30 µM baicalin for 48 h, while xenograft mice were treated with intraperitoneal injection of 0, 100 or 200 mg/kg baicalin for 30 days. The results demonstrated that treatment with baicalin dose-dependently suppressed breast cancer cell invasion, migration and proliferation, and also induced G1/S-phase cell cycle arrest in vitro and in vivo. Baicalin alleviated inflammation injury and inhibited the secretion of tumor necrosis factor (TNF)-α and interleukin (IL)-1β, thus suppressing nuclear factor (NF)-ĸB-p65 activation via inhibition of IĸB kinase. Investigation of the mechanism underlying baicalin activity indicated that it inhibited protein expression of NF-ĸB-p65, leading to NF-ĸB‑induced increased expression of CCND1, BCL2, BIRC2 and BIRC3, thus inhibiting cell proliferation, invasion and migration and suppressing anti-apoptotic factors in vitro and in vivo. In addition, baicalin did not affect non-tumorigenic normal breast epithelial cells. These results indicate that baicalin may exert therapeutic effects in breast cancer.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 53 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao Y, Liu H, Wang H, Hu H, He H, Gu N, Han X, Guo Q, Liu D, Cui S, Cui S, et al: Baicalin inhibits breast cancer development via inhibiting IĸB kinase activation in vitro and in vivo. Int J Oncol 53: 2727-2736, 2018
APA
Gao, Y., Liu, H., Wang, H., Hu, H., He, H., Gu, N. ... Wu, Q. (2018). Baicalin inhibits breast cancer development via inhibiting IĸB kinase activation in vitro and in vivo. International Journal of Oncology, 53, 2727-2736. https://doi.org/10.3892/ijo.2018.4594
MLA
Gao, Y., Liu, H., Wang, H., Hu, H., He, H., Gu, N., Han, X., Guo, Q., Liu, D., Cui, S., Shao, H., Jin, C., Wu, Q."Baicalin inhibits breast cancer development via inhibiting IĸB kinase activation in vitro and in vivo". International Journal of Oncology 53.6 (2018): 2727-2736.
Chicago
Gao, Y., Liu, H., Wang, H., Hu, H., He, H., Gu, N., Han, X., Guo, Q., Liu, D., Cui, S., Shao, H., Jin, C., Wu, Q."Baicalin inhibits breast cancer development via inhibiting IĸB kinase activation in vitro and in vivo". International Journal of Oncology 53, no. 6 (2018): 2727-2736. https://doi.org/10.3892/ijo.2018.4594